Evidence map›Paper›PMID 40097772›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025

Temporal trends in time toxicity of R-CHOP: a nationwide hospital-based database analysis in Japan.

Hiroaki Araie, Tomohisa Seki, Akira Okada, Toshimasa Yamauchi, Masaomi Nangaku, Takashi Kadowaki, Kazuhiko Ohe, Takahiro Yamauchi, Satoko Yamaguchi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Time toxicity in cancer care: a systematic review of definitions and measurement methods.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Time toxicity among patients with cancer: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  3. Experiences and coping strategies of time toxicity in young and middle-aged patients with lymphoma: a descriptive qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  4. The weight of time: experience of time toxicity among advanced cancer patients and their family caregivers-a qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hiroaki AraieDepartment of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.ORCID http://orcid.org/0000-0002-1162-9010
Tomohisa SekiDepartment of Healthcare Information Management, The University of Tokyo Hospital, Tokyo, Japan.
Akira OkadaDepartment of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Toshimasa YamauchiDepartment of Diabetes and Metabolism, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Masaomi NangakuDivision of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Takashi KadowakiDepartment of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Kazuhiko OheDepartment of Healthcare Information Management, The University of Tokyo Hospital, Tokyo, Japan.
Takahiro YamauchiDepartment of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Satoko YamaguchiDepartment of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. syamaguc@m.u-tokyo.ac.jp.

Funding

Japan Society for the Promotion of Science 21K09534
6 · The paper itself

Abstract

purposeWhile the prognosis of patients with cancer has improved, the time burden of treatment has recently been recognized as time toxicity; although, the actual clinical situation remains largely unexplored. This retrospective study aimed to elucidate the time toxicity of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with B-cell lymphoma and the factors influencing it.

methodsWe used a nationwide hospital-based database between January 2010 and November 2021 in Japan. We extracted the claims data of patients with diffuse large B-cell lymphoma and follicular lymphoma who were hospitalized and/or visited hospitals for chemotherapy.

resultsAmong the 7760 R-CHOP administered to 2006 patients, the rate of outpatient therapy increased over time (2010-2015: 17.9%; 2016-2021: 31.8%). In 2016, the median length of hospitalization was the shortest at 13 days (IQR 8-19), which coincided with the peak use of pegylated granulocyte colony-stimulating factor (Peg-G-CSF) during hospitalization in 2015-2016, likely driven by changes in the insurance system. In multivariate analysis, the factors associated with longer hospital stays were older age and poor activities of daily living, whereas the use of Peg-G-CSF, a reduced-dose regimen, and treatment at cancer-designated hospitals were associated with shorter stays.

conclusionThe time toxicity of R-CHOP has improved and may be influenced by the patient's condition, adequate supportive care, changes in the insurance system, and center-specific treatment proficiency.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Large B-Cell, DiffuseAdultAgedAged, 80 and overCyclophosphamideDatabases, FactualDoxorubicinFemaleHospitalizationHumansJapanLength of StayMaleMiddle AgedPrednisoneCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristineB-cell lymphomaR-CHOP regimenSupportive careTime toxicity

Identifiers

PMID40097772
PMCPMC11913952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.